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Abstract
Background: Accurate protein quantification is a vital prerequisite for generating 
meaningful predictions when using systems biology approaches, a method that is 
increasingly being used to unravel the complexities of subcellular interactions and 
as part of the drug discovery process. Quantitative proteomics, flow cytometry, and 
western blotting have been extensively used to define human platelet protein copy 
numbers, yet for mouse platelets, a model widely used for platelet research, evidence 
is largely limited to a single proteomic dataset in which the total amount of proteins 
was generally comparatively higher than those found in human platelets.
Objectives: To investigate the functional implications of discrepancies between levels 
of mouse and human proteins in the glycoprotein VI (GPVI) signalling pathway using a 
systems pharmacology model of GPVI.
Methods: The protein copy number of mouse platelet receptors was determined 
using flow cytometry. The Virtual Platelet, a mathematical model of GPVI signalling, 
was used to determine the consequences of protein copy number differences ob-
served between human and mouse platelets.
Results and conclusion: Despite the small size of mouse platelets compared to human plate-
lets they possessed a greater density of surface receptors alongside a higher concentration 
of intracellular signalling proteins. Surprisingly the predicted temporal profile of Syk activity 
was similar in both species with predictions supported experimentally. Super resolution 
microscopy demonstrates that the spatial distribution of Syk is similar between species, 
suggesting that the spatial distribution of receptors and signalling molecules in activated 
platelets, rather than their copy number, is important for signalling pathway regulation.
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1  | INTRODUC TION
Platelets are small anucleate cells that play a vital role in vascular in-
tegrity and the prevention of excessive bleeding. In addition to this 
key role in hemostasis inappropriate platelet regulation contributes 
to cardiovascular and inflammatory diseases. These platelet-mediated 
processes involve receptor-ligand interactions and the initiation of 
complex signalling cascades. Indeed, current antiplatelet drugs target 
receptor-ligand interactions or signalling cascades to reduce cardiovas-
cular events, but also have the side effect of an increased risk of bleed-
ing. There is therefore a pressing need for safer antiplatelet drugs, 
but the high cost of clinical trials has discouraged drug development. 
Pharmaceutical companies are increasingly adopting quantitative sys-
tems pharmacology (QSP) approaches to determine mechanisms of 
action of new and existing drugs and to better utilize preclinical data 
to optimize clinical trial design.1,2 QSP benefits greatly from published 
quantitative data such as receptor and signalling protein expression lev-
els so that theoretical models can generate more accurate predictions.
Glycoprotein VI (GPVI), a receptor for collagen, laminin, and more 
recently recognized as a receptor for fibrin and fibrinogen, represents 
an attractive antithrombotic target in experimental models with ex-
pression limited to platelets and megakaryocytes.3-11 Following ligand 
engagement a signalling cascade is initiated that culminates in plate-
let activation. While the major components of this pathway are well 
known the underlying mechanism of activation has not yet been fully 
elucidated. Antagonists of the platelet collagen receptor GPVI and 
Bruton tyrosine kinase (Btk) inhibitors (which inhibit signalling evoked 
by GPVI) are recognized as potential antiplatelet drugs,12-19 although 
copy numbers of receptors and signalling molecules involved in the 
GPVI signalling pathway vary widely between individuals and even 
more so between humans and mice.20-22 The functional consequences 
of these differences and the implications for the development of drugs 
that target this pathway are poorly understood.
Quantification of cell protein copy numbers is a critical step 
in the development of a predictive model of platelet activation.23 
Quantitative proteomics, flow cytometry, and western blotting 
have been used to measure human platelet protein copy num-
bers.24-27 Most published reports of platelet protein copy num-
bers have been in humans and tend to focus on a single protein 
of interest. No previous study has provided a systematic com-
parison between different quantification methods or between 
species (human and mouse). Zeiler et al28 published the mouse 
platelet proteome by exploiting quantitative proteomics and re-
ported strikingly higher copy numbers of some proteins in mouse 
compared to human platelets, some an order of magnitude higher 
in mice than humans. This was especially surprising since mouse 
platelets are approximately half the volume of human platelets 
(4.3 versus 7.4 fL)29,30 implying that the densities of these proteins 
within mouse platelets are higher. Few studies of mouse protein 
levels in platelets exist to corroborate these surprising findings. 
One such study quantified mouse Src family kinases using western 
blotting to compare the signal intensity of a platelet lysate with 
known amounts of recombinant protein.31 The copy number of Src 
corroborated well with the Zeiler et al(28) proteomic dataset but 
the copy numbers of Fgr, Fyn, and Lyn differed by up to 240 orders 
of magnitude. This may reflect differences in the binding capacity 
of antibodies for the native protein compared to recombinant pro-
tein or technical issues associated with the analysis of lipid modi-
fied proteins by mass spectrometry.
We sought to independently determine mouse copy numbers of 
key platelet proteins using quantitative flow cytometry as an acces-
sible method to complement mass spectrometry. To address the rel-
evance of differences in protein expression we used GPVI as a model 
receptor. Using a systems pharmacology model of human platelet 
GPVI signalling, which we call the Virtual Platelet,29 the functional 
implications of discrepancies between levels of mouse and human 
proteins in the GPVI signalling pathway were explored. The model 
is a dynamic mathematical model that captures the initial events that 
occur following GPVI receptor activation. We addressed the spatial, 
temporal, and functional questions raised by the mathematical model 
experimentally using mice expressing kinase dead Syk, western 
blotting for phosphorylated Syk at Y525/526, and super-resolution 
microscopy.
2  | METHODS
2.1 | Flow cytometry to determine surface protein 
copy number
Saturating concentrations of fluorescently labelled monoclonal 
antibodies were applied to beads of known antigen binding ca-
pacity (Quantum Simply Cellular; Bangs Laboratories) and 106 
SBF002\1099; European Commission, 
Grant/Award Number: 766118; Deutsche 
Forschungsgemeinschaft, Grant/Award 
Number: SFB/TR 240
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Essentials
• Mouse platelets have strikingly higher copy numbers of 
some proteins compared to human platelets.
• Functional implications of discrepancies are explored 
using a systems pharmacology model of GPVI.
• Interspecies differences in protein expression do not im-
pact the regulation of GPVI signalling.
• Regulation of GPVI signalling is spatially regulated at the 
platelet membrane in humans and mice.
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washed human and mouse platelets. Platelets were also incubated 
with fluorescently labelled IgG to control against nonspecific an-
tibody binding. Bead and platelet fluorescence was read using 
flow cytometry (BD Biosciences; FACSVerse, Accuri CSampler 
Plus). The geometric mean fluorescence was used to construct a 
standard curve to enable the protein copy number on the sur-
face of platelets to be determined. A linear regression was fitted 
to the standard curve. Bead saturation was confirmed by a high 
R2 value close to 1. All monoclonal and FITC conjugated antibod-
ies were from Emfret Analytics (5 µL/106 platelets) except anti-
CLEC-2 (10 µg/mL INU1); anti-CD41 (30 µg/mL MWReg30, BD 
Biosciences) anti-ADAM10 (10 µL/106 platelets R&D systems); 
PE conjugated anti-human GPVI antibody (2.5 µL/106 platelets 
HY101, BD Pharmingen).
2.2 | Flow cytometry to determine intracellular 
protein copy number
8 × 106 human washed platelets suspended in 1× Hepes buffered sa-
line (HBS) were fixed with an equal volume of 4% Paraformaldehyde 
for 10 minutes at room temperature. Platelets were washed three 
times with 1× HBS with pelleting for 15 minutes at 500 g. Platelets 
were permeabilized by incubation with BD Phosflow Perm Buffer 
III for 30 minutes on ice. Following three washes with 1× phos-
phate buffered saline, platelets were incubated with a saturating 
concentration of fluorescein isothiocyanate (FITC) conjugated 
anti-human Syk antibody 4D10 or FITC conjugated IgG control for 
20 minutes at room temperature (20 µg/mL; BD Pharmingen). The 
geometric mean fluorescence was compared to beads of known 
antigen binding capacity as described above to determine the copy 
number of human Syk.
2.3 | Virtual platelet predictions
The mathematical model used to generate computational predic-
tions (the Virtual Platelet) has been described previously.29 The 
model captures the interactions between key proteins downstream 
of collagen receptor GPVI, and simulations form predictions of 
how the proteins interact, to bind, regulate, and activate over time. 
Experimental data describing the copy numbers of the proteins 
GPVI, Syk, c-Cbl, and Tula-2 form model inputs and along with es-
timates of platelet volume, allow numerical solutions of the model 
(carried out with the numerical solver code of R package deSolve32) 
to predict how variation in protein copy numbers affects signalling 
downstream of the GPVI receptor.
Full details of the interactions captured in the model, its equa-
tions, and methods of calibration and validation are available in 
Dunster et al(29) and an interactive online interface to the virtual 
platelet is provide at https ://cardi omaths.shiny apps.io/Virtu alPla 
telet Inter species and the R code is available on request.
Local sensitivity analysis was performed by varying each protein 
copy number by 50% above and below their initial value, the time to 
reach peak Syk activity was calculated according to
where Oa and Oi represent the time to reach the peak in Syk activity in 
respect of the initial protein copy numbers.
2.4 | Human platelet preparation
Human platelets were purified from citrated blood from consenting 
aspirin-free, healthy volunteers following procedures approved by 
the University of Reading Research Ethics Committee and prepared 
as previously described.29
2.5 | Mouse platelet preparation
Procedures were approved by the University of Reading’s Animal 
Welfare and Ethical Review Body. Blood was obtained from C57/
BL6 mice via cardiac puncture into acid citrate dextrose (ACD) fol-
lowing CO2 narcosis and platelets prepared (4 × 10
8 platelets/mL) as 
previously described.33 Platelet aggregation at 2 × 108 platelets/mL 
was followed using light transmission aggregometry as previously 
described.34
2.6 | Syk kinase dead expressing mouse model
Animal experimentation was performed with ethical approval from 
the UK Home Office (PPL P0E98D513) granted to the University 
of Birmingham. Syk kinase-dead (Syk KD) mice refer to the follow-
ing novel mouse strain: C57BL/6NTac-Syktm3515(K396R)Arte (Taconic 
Artemis), which expresses a Syk protein with a K396R point mu-
tation in the presence of cre recombinase. For this study, mice 
were crossed with mice carrying the platelet and megakaryocyte 
specific Pf4 promoter driven cre. Experiments were performed by 
blinding the genotypes prior to the experiment and during analysis.
2.7 | Syk Y525/526 and LAT Y200 phosphorylation 
time course
Human and mouse washed platelets (4 × 108 cells/mL) were pre-
pared under non-aggregating conditions with stirring using an 
AggRAM aggregometer (Helena Bioscience) for the indicated time 
points before lysis as described previously.26 Anti-phospho Syk 
(Abcam; ab58575); anti-phospho LAT (Abcam; ab68139); anti-Actin 
antibody (C-11; Santa Cruz; sc-1615); anti-Syk 4D10 (cell signalling).
Sensitivity Score =
Oa−Oi
Oa
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2.8 | Platelet spreading and staining
For stochastic optical reconstruction microscopy (STORM) imag-
ing washed human and mouse platelets were spread on C-reactive 
protein (CRP) coated 35 mm #1.5 (0.17 mm) glass bottomed dishes 
(MatTek Corporation, USA) as previously described.35 Fixed and 
permeabilized platelets were labelled with a pan-Syk antibody 
(Santa Cruz; N-19:sc-1077 used at 1 µg/mL) at room temperature 
for 1 hour followed by anti-rabbit-Alexa647 (Life Technologies; 
A-21245 used at 1:300 dilution) secondary labelling and Phalloidin-
Alexa488 (1:300 dilution) at room temperature for 1 hour. Samples 
were washed and stored in phosphate-buffered saline (PBS) until 
imaged.
2.9 | STORM imaging
Samples were imaged on a Nikon N-STORM system in dSTORM 
mode which is characterized by a Ti-E stand with Perfect Focus, 
100 × 1.49 NA TIRF objective lens, Agilent Ultra High Power 
Dual Output Laser bed (170-mW, 647-nm laser) for the excitation 
and Andor IXON Ultra 897 EMCCD camera for the image acqui-
sition. To allow fluorophore blinking, samples were imaged in a 
PBS based buffer consisting of enzyme solution (catalase 1 µg/
mL, Tris [2-carboxyelthyl] phosphine hydrochloride 4 mmol/L, 
glycerol 50%, KCl 25 mmol/L, pH 7.5 Tris-HCl 20 mmol/L, glucose 
oxidase 50 µg/mL), glucose solution (glucose 100 mg/mL, glyc-
erin 10%), and reducing agent solution (100 mmol/L MEA). For 
single color (Alexa647) the N-STORM emission cube was used and 
the 405 laser power was then increased by 5% every 30 seconds 
during imaging to reactivate the fluorophore from the dark state. 
20 000 frames were captured using Nikon NIS Elements v4.5 with 
an exposure time of 20 ms, gain 300, and conversion gain 3, and 
reconstructed using STORM analysis module 3.2, applying the 
drift correction and the Gaussian rendering. Five separate fields 
of view (FOV) from three independent experiments were imaged 
for both mouse and human platelets. Identified points, which 
represent individual fluorescent blinking events, were filtered on 
photon count and only those with a count >500 were selected for 
further cluster analysis.
2.10 | Analysis of dSTORM data
After localizing detections (average precision 10 nm) within NIS-
Elements density-based spatial clustering of applications with 
noise (DBSCAN)36 was used to group detections into clusters. For 
DBSCAN the radius of the local neighborhood was set to 25 and 
the minimum number of directly reachable points was set to 10. 
Edge points were included in clusters. Cluster area was calculated 
using the convex hull of all detections within a cluster and cluster 
detection density was defined as the number of detections within 
a cluster divided by the cluster area. Analysis was performed on 
whole fields of view and measurements for all clusters within a 
technical replicate were grouped. This analysis was performed 
using the R package RSMLM.37 To measure cellular area and cal-
culate clusters' per/µm2 regions of interest (ROIs) were drawn 
around the cellular boundary using the epi image within Nikon 
NIS-Elements.
2.11 | Statistical analysis
Data is presented as the mean ± standard deviation. Where indi-
cated statistical analysis was performed using unpaired two-tailed 
t-test or 2-way analysis of variance (ANOVA) with Bonferroni post-
test. All statistical analyses were performed using GraphPad Prism 7.
3  | RESULTS
3.1 | Mouse platelets have a greater density GPVI
Mouse receptor copy numbers were determined by comparing an-
tibody labelled platelets to antibody labelled calibration beads with 
known antigen binding capacities. The mean fluorescence intensity 
of platelets stained with a monoclonal antibody to mouse GPVI 
(JAQ1) (Figure 1A) were compared to beads of known antigen bind-
ing capacity, also labelled with JAQ1 (Figure 1B), which were used to 
construct a calibration curve (Figure 1C). Using this, mouse platelets 
were determined to have 5586 ± 1155 copies of GPVI at the cell 
surface, which is similar to proteomic estimates.
To validate the flow cytometry approach the surface copy number 
of other membrane proteins was determined and compared to the pub-
lished mouse proteomic database (Table 1).28 Copy number was similar 
for CLEC-2, integrins α2, αIIb and α6, GPIbα and P-selectin (activated) 
platelets, whereas the levels of CD9 and ADAM10 were approximately 
one order of magnitude higher when measured using proteomics.
The approach was further validated by using the flow cytometry 
method to determine the surface copy number of human GPVI and 
the intracellular protein copy number of human Syk and comparing 
these to the published human proteomic database (Table 2).24 The 
copy number for human Syk was similar, whereas human GPVI was 
approximately two-fold higher when measured by flow cytometry 
compared to the proteomic estimation.
3.2 | Modelling of mouse GPVI signalling using the 
Virtual Platelet simulation
When comparing the published protein copy numbers for proteins 
involved in the GPVI signalling pathway (GPVI, Syk, Cbl, and TULA-
2) in human and mouse platelets there are some striking differences 
(Figure 1D).24,26,28 One difference of note is the 10-fold increase 
in Syk molecules per mouse platelet compared to human platelets. 
Additionally, due to the smaller size of mouse platelets compared to 
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human platelets, all molecules involved in the initial events down-
stream of GPVI, including the receptor, are at a greater density in 
mouse platelets than in human (Figure 1E).
The Virtual Platelet model of human GPVI signalling29 was used 
to predict how these large differences in mouse platelet protein 
copy number influence signalling. The model is able to predict the 
effects of variability in protein copy number on events downstream 
of the GPVI receptor. We replaced parameters in the Virtual Platelet 
model with mouse protein copy numbers to enable comparison be-
tween the dynamics of GPVI signalling between the two species 
(Figure 2A and 2). The model was used to predict the dynamics of 
Syk tyrosine phosphorylation at positions Y525/Y526 (Y519/520 in 
mouse). Phosphorylation of Y525/Y526 within the activation loop 
of the kinase domain of human Syk is a recognized Syk activation 
marker38 and a critical step in GPVI signalling.
Time-dependent simulations of Syk phosphorylation on the 
activatory loop (Y525/526) in platelets from a hypothetical pop-
ulation of human and mouse donors following ligation of GPVI 
with 10 µg/mL CRP display a similar temporal pattern of tyrosine 
phosphorylation (Figure 2A). The virtual human population show 
a peak in Syk phosphorylation at the activatory site occurring in 
the range of 30-39 seconds following ligand being applied, while 
the virtual mouse population peaked between 18-22 seconds 
(Figure 2B).
3.3 | Experimental time course of human and mouse 
Syk activation corroborates the outcomes of the  
modelling
To corroborate the outcomes of the modelling, experimental time-
courses of Syk phosphorylation at Y525/526 were determined (Figure 2C 
and 2D). Due to the high sequence similarity between human and mouse 
Syk, the phospho-specific antibody raised against phosphorylated tyros-
ines Y525/526 recognizes the corresponding phosphorylated residues 
Y519/520 in mouse platelets.38 The time to maximal tyrosine phospho-
rylation on the Syk activatory loop was determined by quantitative west-
ern blotting, which for mouse was 31 ± 8 seconds and for human was 
34 ± 8 seconds following stimulation with 10 µg/mL CRP (Figure 2E), 
similar to the times to peak predicted by the Virtual Platelet model.
F I G U R E  1   Flow cytometry can be used to determine the copy number of mouse platelet receptors. Saturating concentrations of directly 
dye conjugated monoclonal antibodies against mouse GPVI (JAQ1) were used to label platelets (A) and beads of known antigen binding 
capacity (B). The geometric mean was used to construct a calibration graph, which can then be used to calculate the number of proteins 
exposed at the platelet cell surface (C). Comparison between mouse and human platelet copy numbers taken from this study, Zeiler et al (28) 
and Mazet et al (26) (D). Comparison between mouse and human protein densities, based on platelet volumes of 4.3 and 7.4 fL for mice and 
human, respectively (E)
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3.4 | Mouse platelets are refractory to large 
reductions in the number of Syk molecules
Modelling was used to determine the sensitivity of Syk phospho-
rylation at position Y525/526 in response to variation (±50%) of 
the key components of the Virtual Platelet model (Figure 3). The 
model predicts that the time to peak Syk phosphorylation at the 
activatory site in mouse platelets is, unlike in human platelets, in-
sensitive to a 50% change in Syk copy number. In mouse platelets 
there is no difference in the predicted timing of Syk activation 
following 50% Syk deficiency predicting that mouse platelets 
are insensitive to large variations in Syk protein copy number 
(Figure 3). To test this, using aggregation as a functional end-
point of platelet activation, we used a novel mouse model which 
expresses a kinase dead (K396R) form of Syk in mice contain-
ing a megakaryocyte lineage specific Cre-deleter, Pf4-Cre.39,40 
Platelets express the kinase dead version of Syk and wild-type 
Syk at the same level as Syk in control platelets (Figure S1 in 
supporting information). Heterozygous mice, which have both a 
wild-type Syk allele and a K396R kinase dead Syk allele, were 
compared to litter mate controls (Figure 4A). No significant dif-
ference in total Syk protein levels was observed in the Syk KD HT 
platelets when compared to control platelets (Figure 4B and 4C). 
Using the assumption that Syk KD HT mice express both wild-
type and kinase dead versions of Syk in a 1:1 ratio we compared 
the aggregation of platelets from control and Syk KD HT mice 
in response to 10, 3, and 1 µg/mL of CRP (Figure 4D and 4E). 
No significant difference in percentage platelet aggregation at 
5 minutes following agonist addition was observed between con-
trol and Syk KD HT mouse platelets at any of the concentrations 
of CRP tested (Figure 4E). However, following quantification of 
the time to peak, a statistically significant delay was seen in the 
aggregation of Syk KD HT following the addition of 3 µg/mL CRP 
(Figure 4F). No significant difference in the time to peak was ob-
served following 10 µg/mL CRP.
Tyrosine phosphorylation on the Syk activatory loop was deter-
mined by quantitative western blotting (Figure 4G-I). As the model 
predicts, no significant difference was seen in the time to maximal 
tyrosine phosphorylation on the Syk activatory loop between con-
trol and Syk KD HT mice following stimulation with 10 µg/mL CRP. 
In addition, no significant difference was observed in the phosphor-
ylation of the downstream signalling molecule LAT at position Y200 
(Figure S2 in supporting information).
Despite the competition of wild-type and kinase dead versions 
of Syk in the heterozygous mice and the dominant negative effect 
this has on signalling outcomes, heterozygous platelets expressing 
both the wild type and kinase dead version of Syk largely have no 
observable phenotype when stimulated with 10 µg/mL CRP and 
only a minor phenotype when stimulated using a reduced concen-
tration of CRP. These data validate the model by demonstrating 
that mouse platelets are relatively resistant to a 50% variation in 
functional Syk.
3.5 | Spatial organization of Syk in mouse and 
human platelets
The spatial distribution of receptors and signalling molecules is an 
important consideration in the regulation of signalling pathways. 
We hypothesized that as the initial signalling events are similar 
between mouse and human platelets, both in the Virtual Platelet 
model and in the experimental outcomes, signalling may be regu-
lated by the spatial distribution of signalling molecules. To identify 
and quantify the spatial distribution of Syk in human and mouse 
platelets the localization of Syk was imaged by dSTORM super 
resolution microscopy using an Alexa 647 conjugated secondary 
labelled pan-Syk antibody, which cross reacts with both human 
and mouse Syk. The DBSCAN algorithm was used to determine 
TA B L E  1   Copy number of major mouse platelet receptors. Copy 
number of major mouse platelet receptors determined by flow 
cytometry values presented as the mean ± S.D n> 3
Mouse platelet copy number (copy number ± copies)
Platelet receptor Proteomicsa Flow cytometry
GPVI 7822 ± 637 5586 ± 1155
α2 17 591 ± 1260 25 418 ± 4594
CLEC-2 41 652 ± 7759 42 816 ± 637
CD9 135 059 ± 11 862 10 544 ± 2481
ADAM10 9889 ± 1151 1175 ± 303
P-selectin 35 970 ± 2712  
P-selectin (resting)  550 ± 290
P-selectin (activated)  53 538 ± 8875
αIIb (CD41) 10 6624 ± 7905 142 027 ± 11 782
α6 20 672 ± 1535 11 312 ± 1593
GPIbα 46 154 ± 5106 61 851 ± 26 852
Syk 23 286 ± 4114  
Cbl 3241 ± 416  
Tula2 21 469 ± 3083  
Note: A comparison has been made with the available mouse 
quantitative proteomics data taken from. 28
aZeiler et al. 28 
TA B L E  2   Copy number of human GPVI and human Syk. Copy 
number of human GPVI and human Syk determined by flow 
cytometry, values presented as the mean ± S.D n ≥ 3
Human platelet copy number (copy number ± copies)
Platelet Protein Proteomicsa Flow cytometry
GPVI 9600a 25 384 ± 3639
Syk 4600a 5192 ± 1055
Note: A comparison has been made with the available human 
quantitative proteomics data taken from.24
aBurkhart et al.24 
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F I G U R E  2   Virtual platelet predictions of Syk activity in a hypothetical population of mouse and human platelets is supported by the 
experimental outcomes. A, The results of 200 simulations of the Virtual Platelet are shown. Each line represents a prediction of how Syk 
phosphorylation changes over time in response to protein copy numbers randomly selected across their normal range (Human: GPVI, 
5000 +/−12%; Syk, 2763 +/−22%, c-Cbl, 2581 +/−25%. Mouse: GPVI, 5586 +/−12%; Syk, 23 286 +/−22%, c-Cbl, 3241 +/− 25%). Simulations 
representing Syk phosphorylation in a hypothetical mouse platelet (n = 100) shown in red or in a human platelet (n = 100) in blue. B, A 
summary of model predictions for the time to reach maximal peak Syk activity with each simulation denoted graphically by a circle. C, 
Representative time course of Syk Y525/Y526 phosphorylation in human and mouse washed platelets following GPVI ligation with 10 µg/
mL CRP. Actin acts as a loading control. D, Quantification of mouse and human Syk Y525/Y526 phosphorylation time courses. Mean ± S.D, 
n = 5. E, Time to maximal Syk Y525/Y526 phosphorylation. Line indicates the mean ± S.D. P = .5796 Statistical analysis was performed with 
unpaired t test
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F I G U R E  3   Mouse platelets are refractory to large reductions in the number of Syk molecules. Modelling suggests that the sensitivity of 
Syk phosphorylation to variation in protein copy numbers varies between human and mouse platelets. Time to maximal Syk phosphorylation 
in a hypothetical population of human and mouse platelets is shown, where the copy number of each protein was varied by 50% above and 
below their initial value. A positive sensitivity score represents an increase in the time to reach peak activity and a negative score represents 
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Syk cluster size, number, and detection density within clusters 
(Figure 5A and 5B). DBSCAN identifies clusters by grouping points 
together within a defined local distance provided a minimum 
number of points can be found within that defined distance. For 
this analysis, a radius of 25 nm was used and the minimum num-
ber of points located within the defined radius was 10. These 
F I G U R E  4   A, Genotyping strategy confirming the presence of both a Syk wild-type (WT) allele and kinase dead (KD) version under the 
control of PF4-Cre in the heterozygous mice (HT) and homozygous mice (HO). B, Total Syk protein levels were measured by western blot in 
control (WT) and Syk KD HT (HT) mice using two different anti-Syk antibodies. C, Quantification of Syk levels in platelets from WT and Syk 
KD HT mice. Mean ± S.D, n = 3. 4D10 P = .146, N19 P = .305 Statistical analysis was performed with unpaired t test. D, Platelet aggregation 
of washed control (WT) and heterozygous (HT) mice induced by 10 and 3 µg/mL CRP (addition of agonist indicated by arrowhead). E, 
Quantification of % aggregation at 5 minutes of control (WT) and Syk KD HT (HT) platelets. Mean ± S.D, n ≥ 3. Statistical analysis was 
performed with a two-way ANOVA with Bonferroni posttest (ns; P > .05). F, Quantification of time to peak of control (WT) and Syk KD HT 
(HT) platelets. Mean ± S.D, n ≥ 3. Statistical analysis was performed with a two-way ANOVA with Bonferroni post-test (ns; P > .05, *P < .05). 
G, Representative time course of Syk Y525/Y526 phosphorylation in WT and Syk KD HT mouse washed platelets following GPVI ligation 
with 10 µg/mL CRP. Actin acts as a loading control. H, Quantification of control (WT) and Syk KD HT (HT) Syk Y525/Y526 phosphorylation 
time courses. Mean ± S.D, n = 3. I, Time to maximal Syk Y525/Y526 phosphorylation. Line indicates the mean ± S.D. P = .193. Statistical 
analysis was performed with unpaired t test
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user-defined conditions minimized background noise and mini-
mized the merging of discrete clusters together (Figure S3 in sup-
porting information). While mouse platelets had significantly more 
detections per cluster, a larger cluster area, and an increased num-
ber of clusters per unit area (Figure 5C, 5D, and 5E) there was no 
significant difference in the Syk detection density within clusters 
between human and mouse platelets (Figure 5F).
4  | DISCUSSION
Quantification in biology is of increasing importance, not only to 
identify potential new drug targets, but to also understand the im-
plications signalling perturbations and variations have on functional 
outcomes by generating models reliable enough for in silico research. 
Here we use flow cytometry to quantify the level of surface recep-
tors and to quantify changes in the copy number of membrane re-
ceptors at the surface of platelets.
All platelet surface receptors tested in this study, except the 
metalloproteinase ADAM10 and the tetraspanin CD9, were within 
two-fold of those determined by quantitative proteomics. The 
flow cytometry approach for these two proteins gave surface pro-
tein copy numbers that were 10 times lower that determined by 
proteomics. These differences may indicate that these proteins have 
significant intracellular pools or decreased antibody binding due to 
steric hindrance. Indeed, studies in other cell types demonstrate 
that, in addition to surface expression, ADAM10 is also localized to 
intracellular pools41 but it is not known if this is the case in platelets. 
Tetraspanins are recognized as membrane organizers, interacting 
with other tetraspanins and also other interacting partners such as 
integrins.42 Clustering of CD9 with other tetraspanins and mem-
brane partners in the cell membrane may lead to reduced antibody 
binding due to steric hindrance.
While available proteomic datasets provide an estimation of ab-
solute numbers of proteins, these data can be combined with flow 
cytometry to determine the copy number of proteins expressed at 
the surface and used to quantify changes in surface expression. 
For example, as expected, resting mouse platelets have very little 
P-selectin molecules at their surface (550 ± 290 molecules per plate-
let). When activated this increases to 53 538 ± 8875 molecules per 
platelet. This value is in the same order of magnitude as the total 
amount of P-selectin identified in the mouse proteomic dataset 
(35 970 ± 2712 molecules per platelet). Proteomics provides an in-
dication of total P-selectin protein copy number suggesting that fol-
lowing platelet activation the majority of P-selectin is exposed to the 
surface of platelets.
F I G U R E  5   Spatial distribution of Syk in mouse and human platelets. Representative plot of clusters in a human platelet (A) and a mouse 
platelet (B) spread on CRP. Clusters were identified using DBSCAN with a radius of 25 nm and a minimum number of points as 10. Each 
cluster is identified by a different color, the black points are background points which do not meet the criteria to be included in a cluster. 
Quantification of the number of detections per cluster (C), cluster area (D), number of clusters per spread platelet area (E), and the detection 
density within clusters (F) in human and mouse platelets. Mean ± S.D, n = 3 *P ≤ .05 **P ≤ .01 Statistical analysis was performed with 
unpaired t test
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There were 42 816 ± 637 copies of CLEC-2 identified on the 
surface of mouse platelets compared to only 2016 ± 239 copies re-
ported on human platelets.43 The copy number of human CLEC-2 
determined by flow cytometry supports the Burkhart et al (24) 
proteomics dataset, which identified 3700 copies of CLEC-2 per 
human platelet. The copy number of mouse CLEC-2 by flow cytom-
etry strongly supports the mouse proteomic data, which identified 
41 652 ± 7759 copies of CLEC-2 per mouse platelet.28 Our data 
suggest that mouse platelets express approximately 20 times more 
CLEC-2 at their surface than human platelets. The increase in pro-
tein copy number may contribute to the recent finding that mouse 
platelets can adhere to and form aggregates on recombinant mouse 
podoplanin at high shear rates whereas human platelets are unable 
to do so.44,45 The difference in CLEC-2 copy number raises the sug-
gestion that high levels of Syk in mouse platelets may support other 
Syk dependent signalling events such as those mediated by CLEC-2.
When comparing the copy numbers of signalling molecules as-
sociated with the GPVI signalling pathway we were surprised to find 
that there was a 10-fold increase in Syk molecules in mouse platelets 
compared to human. Considering how tyrosine kinases play a piv-
otal role in platelet receptor signal transduction we sought to use 
the Virtual Platelet model to explore the effect protein copy num-
ber may have on GPVI signalling in mouse platelets, particularly in 
the regulation of Syk. The model corroborated experimental data 
demonstrating that phosphorylation of the tyrosines within the Syk 
activatory loop follow a similar time course in mouse and human 
platelets despite the differences in copy number of Syk.
The Virtual Platelet, a mathematical model of platelet signalling, 
has allowed the role and importance of specific signalling molecules 
involved in platelet activation to be determined. We have used the 
Virtual Platelet to investigate the functional implications of discrep-
ancies between levels of mouse and human proteins in the GPVI sig-
nalling pathway. This has shed light on the molecules and processes 
within platelet cells that regulate GPVI mediated signalling. Models, 
like the Virtual Platelet, have the potential to aid the development of 
new anti-platelet therapies, enable correlations between preclinical 
toxicity screening and clinical outcomes, and may facilitate person-
alized therapy.
The Virtual Platelet simulation that used the mouse protein lev-
els predicted a slightly larger difference in Syk temporal regulation 
compared with the experimental data. This may lie in the subtle dif-
ference in the regulation of Tula-2, a histidine tyrosine phosphatase 
that negatively regulates Syk, between mouse and human.46 Human 
Tula-2 has been reported to have a dependence on protein kinase C 
(PKC). Studies used pan-inhibitors of PKC suggests that PKC regula-
tion of TULA-2 negatively regulates Syk activation. Mouse platelets 
have no reported role for PKC in Tula-2 regulation.47 Mouse platelets 
may compensate for the loss of this second level of regulation by 
having greater levels of Tula-2 compared to human.
The counterintuitive increase in human platelet activity in re-
sponse to increases or decreases in Syk copy numbers reflects 
Syk’s tight control of its own activation and inhibition. The copy 
numbers in human platelets are in balance so that Syk controls its 
own activation. A mouse model expressing a kinase dead version of 
Syk was used to investigate the impact a loss of functional Syk had 
on GPVI mediated signalling. Despite the competition of wild-type 
and kinase dead versions of Syk in the heterozygous mice and the 
dominant negative effect this may have on signalling outcomes, het-
erozygous platelets expressing both the wild-type and kinase dead 
version of Syk largely behaved like control platelets in the exper-
imental conditions tested. The insensitivity of mouse platelets to 
variation in Syk leads to the hypothesis that in mice, concentrations 
of Syk may be more tightly controlled upstream, at the cell mem-
brane. Indeed, considerable evidence suggests that the spatial distri-
bution of signalling assemblies is highly regulated. Many membrane 
receptors do not function as single signalling units but instead asso-
ciate in multimolecular complexes with the formation of submicron 
clusters implicated in the initiation, maintenance, and down regula-
tion of signalling pathways.48-50
GPVI has been shown to oligomerize in response to a range of 
GPVI ligands in human platelets.35 dSTORM allowed fluorophore 
molecules to be detected and located with high spatial precision. 
Combined with cluster analysis the relative localization of Syk mol-
ecules in human and mouse platelets was determined. Despite the 
10-fold difference in the copy number of Syk in mouse platelets 
there was only a 2.7-fold increase in the number of clusters per 
spread platelet area and a 1.3- and 1.2-fold increase in the cluster 
area and the number of detections per cluster, respectively. Overall 
there was no significant difference in the relative density of Syk 
within the identified clusters. This suggests that regulation of GPVI 
signalling may be at the level of receptor and explains why, despite 
large differences in protein copy number, the regulation of GPVI 
mediated signalling is similar between mouse and human platelets.
In conclusion, we have used a flow cytometry-based method to 
validate the available mouse proteomics data, providing a means 
to quantify mouse platelet surface protein expression and changes 
induced following platelet activation. Using a systems pharmacol-
ogy model of human platelet GPVI signalling, the Virtual Platelet, in 
combination with quantitative flow cytometry and super resolution 
microscopy, we have identified that, despite large differences in pro-
tein copy number, the regulation of proximal signalling events down-
stream of GPVI is tightly regulated at the level of the cell membrane 
in both human and mouse platelets.
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